Role of exosome-associated adenosine in promoting angiogenesis.
Exosomes
adenosine
adenosine receptors
angiogenesis
endothelial cells
extracellular vesicles
Journal
Vessel plus
ISSN: 2574-1209
Titre abrégé: Vessel Plus
Pays: United States
ID NLM: 101726367
Informations de publication
Date de publication:
2020
2020
Historique:
entrez:
4
6
2020
pubmed:
4
6
2020
medline:
4
6
2020
Statut:
ppublish
Résumé
The role of exosomes in different physiological and pathological settings is an emerging field of great current interest. One hallmark of exosomes is the promotion of blood vessel formation. Exosomes of different cellular origin have been shown to be enriched in angiogenic proteins which directly promote angiogenesis. In addition, exosomes are also efficacious producers of adenosine and potentially encapsulate adenosine in their lumen. The adenosine content of exosomes has been linked to their immunosuppressive effects. In this communication, we consider the possibility that adenosine production by tumor cell-derived exosomes may represent a novel pathway for stimulation of angiogenesis in the tumor microenvironment.
Identifiants
pubmed: 32490359
doi: 10.20517/2574-1209.2019.37
pmc: PMC7266301
mid: NIHMS1589048
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : NIDDK NIH HHS
ID : R01 DK068575
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL069846
Pays : United States
Organisme : NIDCR NIH HHS
ID : U01 DE029759
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK091190
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA256068
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL109002
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK079307
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA168628
Pays : United States
Déclaration de conflit d'intérêts
Conflicts of interest All authors declared that there are no conflicts of interest.
Références
Circ Res. 2007 Nov 26;101(11):1075-7
pubmed: 18040023
J Extracell Vesicles. 2014 Aug 04;3:
pubmed: 25143819
Crit Rev Oncol Hematol. 2018 Jun;126:24-31
pubmed: 29759563
Exp Biol Med (Maywood). 2015 Nov;240(11):1472-9
pubmed: 25966978
Am J Physiol Lung Cell Mol Physiol. 2019 Apr 1;316(4):L691-L700
pubmed: 30758991
J Immunol. 2011 Jul 15;187(2):676-83
pubmed: 21677139
Mol Cancer Res. 2018 Nov;16(11):1798-1808
pubmed: 30042174
Clin Exp Immunol. 2014 Aug;177(2):531-43
pubmed: 24749746
Adv Clin Chem. 2016;74:103-41
pubmed: 27117662
Circ Res. 2003 Mar 21;92(5):485-92
pubmed: 12600879
Int J Mol Sci. 2019 Nov 14;20(22):
pubmed: 31739402
Am J Physiol Regul Integr Comp Physiol. 2005 Aug;289(2):R283-R296
pubmed: 16014444
Nat Cell Biol. 2008 Dec;10(12):1470-6
pubmed: 19011622
Circ Res. 2007 Nov 26;101(11):1130-8
pubmed: 17901362
J Leukoc Biol. 2015 Jan;97(1):9-18
pubmed: 25387836
Hypertension. 2002 Feb;39(2 Pt 2):530-5
pubmed: 11882603
Oncogene. 2013 May 30;32(22):2747-55
pubmed: 22797057
Am J Physiol. 1993 Jul;265(1 Pt 2):H131-8
pubmed: 8342624
Expert Opin Ther Targets. 2018 May;22(5):409-417
pubmed: 29634426
BMC Physiol. 2005 Jun 20;5:10
pubmed: 15967042